KC S, Tragulpiankit P*, Gorsanan S, Edwards R. BMC Pharmacology and Toxicology 2013; 14-16.
Characteristics of Renin Angiotensin System Blockers-induced Angioedema in Thailand.
Win TSZ (Win, T. S. Z.), Nathisuwan S, Chaiyakunapruk N, Suwankesawong W, Tanyasaensook K, Dilokthornsakul P. International journal of clinical pharmacy. 2013; 35(6): 1292-1292 IF=0.89500000000000002
Boonmuang P, Nathisuwan S*, Chaiyakunapruk N, Suwankesawong W, Pokhagul P, Teerawattanapong N, Supsongserm P. Drug Safety 2013; 36(9): 779-787 IF=2.6200000000000001
Maenthaisong R, Tacconelli S, Sritara P, Del Boccio P, Di Francesco L, Sacchetta P, Archararit N, Aryurachai K, Patrignani P*, Suthisisang C. International Journal of Immunopathology and Pharmacology 2013; 26: 403-417 IF=2.5070000000000001
Cost-effectiveness of CYP2C9 and VKORC1 genetic testing to predict warfarin guided dose in Thai population.
Salek S, Dumrongprat K, Nathisuwan S. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 2013; 35(5): 1005-1005. IF=0.85899999999999999
Boonmuang P, Nathisuwan S*, Chaiyakunapruk N, Suwankesawong W, Pokhagul P, Teerawattanapong N, Supsongserm P. Drug Safety 2013; 36(7): 583-584 IF=2.6200000000000001
Wang L, Li L, Sun Y, Tian Y, Li Y, Li C, Junyaprasert VB, Mao S*. European Journal of Pharmaceutical Sciences 2013; 50(3เม.ย.): 263-271 IF=3.0049999999999999
In vitro-in vivo correlation study for the dermatopharmacokinetics of terbinafine hydrochloride topical cream.
Saeheng S, Nosoongnoen W, Varothai S, Sathirakul K. Drug Dev Ind Pharm. 2013;39(9):1372-1377.
Influence of chemical penetration enhancers on skin permeability of ellagic acid-loaded niosomes.
Junyaprasert VB*, Singhsa P, Jintapattanakit A Asian Journal of Pharmaceutical Sciences 2013; 8(2): 110-117
Kc S, Tragulpiankit P*, Edwards IR, Gorsanan S. International Journal of Risk and Safety in Medicine 2013; 25(1): 1-16
Meta-analysis of the efficacy and safety of rivaroxaban for treatment of acute symptomatic deep vein thrombosis.
Poolsup N, Suksomboon N*, Wattanasopon K, Kosumwisaisakul B, Chaopantanon P. European Journal of Pharmaceutical Sciences 2013; 50(suppl 1): 104-106 IF=3.0049999999999999
This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.